Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy

Executive Summary

Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.

You may also be interested in...



Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet

Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds. 

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth

Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel